$50.01
0.06% yesterday
Nasdaq, Dec 24, 07:47 pm CET
ISIN
US0327241065
Symbol
ANAB

AnaptysBio, Inc. Stock price

$50.01
+8.06 19.21% 1M
+26.69 114.45% 6M
+36.77 277.72% YTD
+36.12 260.04% 1Y
+20.78 71.09% 3Y
+27.76 124.76% 5Y
+33.01 194.18% 10Y
+33.01 194.18% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.03 0.06%
ISIN
US0327241065
Symbol
ANAB
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.5b
Net debt
$82.9m
Cash
$249.0m
Shares outstanding
27.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.2 | 6.4
EV/Sales
8.7 | 6.8
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
14.7%
Return on Equity
-204.9%
ROCE
-9.1%
ROIC
-
Debt/Equity
-11.3
Financials (TTM | estimate)
Revenue
$169.5m | $214.9m
EBITDA
$-28.1m | $-8.2m
EBIT
$-28.7m | $15.7m
Net Income
$-84.6m | $-34.9m
Free Cash Flow
$-145.3m
Growth (TTM | estimate)
Revenue
196.4% | 135.5%
EBITDA
80.9% | 92.9%
EBIT
80.5% | 113.6%
Net Income
48.9% | 76.0%
Free Cash Flow
-40.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-16.6% | -3.8%
EBIT
-16.9%
Net
-49.9% | -16.3%
Free Cash Flow
-85.8%
More
EPS
$-2.9
FCF per Share
$-5.3
Short interest
40.2%
Employees
136
Rev per Employee
$670.0k
Show more

Is AnaptysBio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

AnaptysBio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a AnaptysBio, Inc. forecast:

16x Buy
84%
3x Hold
16%

Analyst Opinions

19 Analysts have issued a AnaptysBio, Inc. forecast:

Buy
84%
Hold
16%

Financial data from AnaptysBio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
169 169
196% 196%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 45 45
6% 6%
27%
- Research and Development Expense 153 153
1% 1%
90%
-28 -28
81% 81%
-17%
- Depreciation and Amortization 0.57 0.57
8% 8%
0%
EBIT (Operating Income) EBIT -29 -29
81% 81%
-17%
Net Profit -85 -85
49% 49%
-50%

In millions USD.

Don't miss a Thing! We will send you all news about AnaptysBio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AnaptysBio, Inc. Stock News

Neutral
PRNewsWire
10 days ago
WASHINGTON , Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP). Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the e...
Neutral
GlobeNewsWire
30 days ago
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:
Negative
Investors Business Daily
about one month ago
AnaptysBio stock buckled Friday after the biotech company and GSK filed competing lawsuits against one another over a licensing deal.
More AnaptysBio, Inc. News

Company Profile

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Head office United States
CEO Daniel Faga
Employees 136
Founded 2005
Website www.anaptysbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today